AASLD: Erin Meadows firstname.lastname@example.org
IDSA: Jennifer Morales email@example.com
HCVguidelines.org — a website developed by the American Association of the Study for Liver Diseases and the Infectious Diseases Society of America to provide up-to-date guidance on the treatment of hepatitis C — has added to its guidance and resources for the diagnosis and treatment of hepatitis C.
New additions to the website include a primer on HCV resistance, guidance on treating people who have undergone kidney transplantation, and guidance on HCV in pregnant women and children. Additionally, the entire guidance has been updated to reflect recent approvals of glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir.
“HCVguidelines.org is a valuable resource for researchers, clinicians, health professionals and the broader hepatology and infectious disease communities,” say panel co-chairs Raymond T. Chung, MD; Arthur Y. Kim, MD; Susanna Naggie, MD; and Hugo E. Vargas, MD. “As new HCV therapies become available, and additional resources are needed to navigate diagnosis and treatment, our panel remains focused on ensuring complete, high-quality and timely guidance.”
The new sections of Guidance include:
- HCV Resistance Primer: Provides key information including terminology, guidance on when and when not to provide resistance testing, approaches to overcoming resistance, and several other topics.
- Kidney Transplant Patients: Includes guidance for use of DAA therapy in patients who have undergone kidney transplant.
- HCV in Pregnancy: Includes recommendations for testing, treating, and monitoring pregnant women with HVC as well as a section on key postpartum issues.
- HCV in Children: Includes recommendations for testing children, as well as information for counseling parents on transmission and prevention and monitoring and medical treatment.
Visit www.HCVguidelines.org for updates regarding the release of these and other sections of the guidance.
AASLD is a medical subspecialty society representing clinicians and researchers in liver disease. The work of our members has laid the foundation for the development of drugs used to treat patients with viral hepatitis. Access to care and support of liver disease research are at the center of AASLD’s advocacy efforts.
AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. AASLD was founded in 1950 by a small group of leading liver specialists and has grown to an international society responsible for all aspects of hepatology.
The Infectious Diseases Society of America (IDSA) is an organization of physicians, scientists, and other health care professionals dedicated to promoting health through excellence in infectious diseases research, education, prevention, and patient care. The Society, which has nearly 10,000 members, was founded in 1963 and is based in Arlington, VA. For more information, see idsociety.org.